Sunshine Biopharma, Inc.
SBFM
$1.40
-$0.02-1.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.15% | 18.04% | 24.93% | 41.58% | 67.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.15% | 18.04% | 24.93% | 41.58% | 67.29% |
| Cost of Revenue | -13.81% | 18.98% | 27.18% | 40.37% | 92.53% |
| Gross Profit | 45.27% | 15.98% | 20.44% | 44.01% | 20.67% |
| SG&A Expenses | 34.85% | 8.07% | 70.48% | 52.55% | 21.29% |
| Depreciation & Amortization | 42.44% | 52.11% | 54.25% | 73.66% | 45.85% |
| Other Operating Expenses | -22.70% | 45.19% | 41.67% | 7.41% | 50.93% |
| Total Operating Expenses | -1.59% | 14.68% | 31.19% | 41.63% | 60.79% |
| Operating Income | 21.72% | 4.06% | -71.64% | -41.94% | -25.09% |
| Income Before Tax | -136.28% | 3.29% | -122.07% | -60.95% | -2.90% |
| Income Tax Expenses | 39.13% | -279.46% | -158.42% | 424.88% | -491.90% |
| Earnings from Continuing Operations | -258.24% | 8.10% | -72.66% | -83.85% | 45.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -258.24% | 8.10% | -72.66% | -83.85% | 45.21% |
| EBIT | 21.72% | 4.06% | -71.64% | -41.94% | -25.09% |
| EBITDA | 24.40% | 5.89% | -72.27% | -40.33% | -24.35% |
| EPS Basic | 96.04% | 78.20% | 98.83% | 98.14% | 86.03% |
| Normalized Basic EPS | 98.79% | 77.06% | 98.50% | 98.37% | 73.77% |
| EPS Diluted | 96.04% | 78.20% | 98.83% | 98.14% | 86.03% |
| Normalized Diluted EPS | 98.79% | 77.06% | 98.50% | 98.37% | 73.77% |
| Average Basic Shares Outstanding | 8,946.48% | 321.53% | 14,735.17% | 9,803.13% | 291.34% |
| Average Diluted Shares Outstanding | 8,946.48% | 321.53% | 14,735.17% | 9,803.13% | 291.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |